Evolent Health, Inc. EVH

Rank #1574 · NYSE · $0.5B market cap

Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.

Score

46.1

P/E

-4.3

P/B

0.56

ROE

-13.2%

Op. Margin

-3.6%

Debt Ratio

157%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆

Average

P/E -4.3x, P/B 0.56x. Ranks in the top 49% of the universe.

Profitability ★☆☆☆☆

Weak

ROE -13.2%. Ranks in the top 76% of the universe.

Safety ★★☆☆☆

Average

Debt ratio 157%. Ranks in the top 54% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 45.3% year over year. Ranks in the top 8% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2015	–	$-0.0B	$0.0B	$-0.0B	–	0
2016	–	$0.0B	$-0.0B	$0.6B	–	12
2017	–	$-0.0B	$0.3B	$0.7B	–	41
2018	$0.3B	$-0.2B	$-0.2B	$1.0B	-93.4	26
2019	$0.4B	$-0.1B	$-0.1B	$1.1B	-16.7	47
2020	$0.6B	$-0.0B	$-0.1B	$0.9B	-7.6	62
2021	$0.7B	$-0.3B	$-0.3B	$0.6B	-45.0	121
2022	$0.9B	$-0.3B	$-0.3B	$0.9B	-28.4	78
2023	$0.9B	$-0.0B	$-0.0B	$0.9B	-4.7	111
2024	$1.4B	$0.0B	$-0.0B	$0.7B	0.3	207
2025	$2.0B	$-0.1B	$-0.1B	$0.9B	-3.6	157